Product
OPT-821
3 clinical trials
2 indications
Indication
NeuroblastomaIndication
High-risk NeuroblastomaClinical trial
Phase II Trial of a Bivalent Vaccine With the Immunological Adjuvant OPT-821 (QS-21), in Combination With Randomization of Oral β-glucan, for High-Risk NeuroblastomaStatus: Recruiting, Estimated PCD: 2026-03-21
Clinical trial
Phase I/II Trial of a Bivalent Vaccine With Escalating Doses of the Immunological Adjuvant OPT-821, in Combination With Oral β-glucan for High-Risk NeuroblastomaStatus: Active (not recruiting), Estimated PCD: 2025-05-01
Clinical trial
Phase II Trial of a Bivalent Vaccine With the Immunological Adjuvant OPT-821 (QS-21), in Combination With Oral β-glucan and Randomization of GM-CSF, for High-risk NeuroblastomaStatus: Recruiting, Estimated PCD: 2025-06-15